Peptilogics News and Activities

Acquisition, funding and merger involving Peptilogics.

• Peptilogics has just announced a $78 Million fundraising (posted on October 16 2025).

View the org chart displaying its 13 main executives

Most searched biographies at Peptilogics

• Jonathan Steckbeck, Chief Executive Officer
• Dietrich Stephan, Chairman of the Board
• Hannes Holste, Director

Create your alert
to follow the executive moves at Peptilogics.

Peptilogics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (posted on June 1 2026)..

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Peptilogics

• Peptilogics Begins Pivotal Trial of First-Ever Drug Designed to Cure Medical Device-Related Infections | Peptilogics
• 2026 | Peptilogics
• Peptilogics Raises $78 Million to Advance Zaloganan Into Pivotal Trial | Peptilogics
• 2025 | Peptilogics
• Peptilogics Reports Positive 180-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI) | Peptilogics
• Peptilogics Reports Positive 90-Day Top Line Interim Data From Phase 1b Trial of PLG0206 in Patients with Periprosthetic Joint Infection (PJI) | Peptilogics
• Peptilogics Completes Phase 1b Trial Enrollment and Will Present Interim Top-line Safety and Tolerability Data of PLG0206 in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection After a Total Knee Arthroplasty at ECCMID 2023 | Pept
• 2023 | Peptilogics
• Peptilogics Hosting Panel Discussion with Leading Industry Experts on the High Unmet Medical Need and Opportunity in Periprosthetic Joint Infections (PJI) | Peptilogics
• Peptilogics to Present Data at IDWeek 2022 on PLG0206, an Engineered Antimicrobial Peptide Targeting Bacteria Causing Periprosthetic Joint Infection | Peptilogics
• View more press releases Close

Social media about Peptilogics

• Peptilogics on Wikipedia, Google News & Yahoo Finance
• Peptilogics on LinkedIn, X (Twitter) & YouTube